Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05351164 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
A Phase 2 study of Lipomatosis, Multiple Symmetrical, sponsored by University of Michigan.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05351164 is a Phase 2 study of Lipomatosis, Multiple Symmetrical that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05351164, a Phase 2 study of Lipomatosis, Multiple Symmetrical, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
Participants (homozygous MFN2 \[gene that provides instructions to produce the Mitofusin 2 protein\] R707W) will be treated with Metreleptin, and effects on body composition, metabolic parameters and safety will be assessed over a 6 month intervention period. Additional safety will be assessed for 1 more year (up to 1.5 years total) in which adverse event data will be collected.
Conditions Studied
Interventions
- DRUG Metreleptin
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05351164
The ClinicalTrials.gov registry entry for NCT05351164 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipomatosis, Multiple Symmetrical appearing as the primary indexed condition, and to 1 intervention - of which Metreleptin is the first listed.
NCT05351164 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05351164 about?
NCT05351164 is a clinical study titled "Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)". Participants (homozygous MFN2 \[gene that provides instructions to produce the Mitofusin 2 protein\] R707W) will be treated with Metreleptin, and effects on body composition, metabolic parameters and safety will be assessed over a 6 month intervention period. Additional safety will be assessed for 1...
What is the current status of trial NCT05351164?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-08-01. Estimated completion is 2028-10.
What conditions does trial NCT05351164 study?
This clinical trial studies the following conditions: Lipomatosis, Multiple Symmetrical.
What interventions are being tested in trial NCT05351164?
The interventions under investigation include: Metreleptin (DRUG).
Who is sponsoring clinical trial NCT05351164?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05351164 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.